Partnership interests

In Licensing
- Global or Regional (in priority EU/China/Japan)

Discovery & Early-stage Clinical Focus
- Cancer cell Targeting
  - Synthetic lethality
  - Apoptosis
  - Precision oncology
  - Epigenetic regulators
- Immuno-oncology
  - Tumor micro-environment
  - T cell targeting

Late-stage Clinical Focus
- Hematologic tumors (NHL, ALL, AML)
- Solid tumors; GI as a priority

Modalities
- Small molecules and biologics (mAbs/bispecifics, ADCs)

Out Licensing
- Global or Regional
- Co-Development, Research Collaborations

Active Oncology Partnerships

Global BD
Frédéric Scaërou, PhD
Global Head, Business Development Oncology
Mobile: +33 6 30 00 14 40
frederic.scaerou@servier.com

Valérie Agrapart, PharmD
Director, Business Development Oncology
Mobile: +33 6 33 32 46 43
valerie.agrapart@servier.com

Jérôme Roussel, PharmD
Director, Business Development Oncology/Diagnostics
Mobile: +33 6 76 41 46 42
jerome.roussel@servier.com

Local BD
USA
Pat Fetaya, MBA, MSc
Head, US Business Development, Servier Pharmaceuticals
Mobile: +1.609.285.8275
pat.fetaya@servier.com

Asia
Cynthia Wang, MBA, MSc
Director, Global Business Development Asia-Pacific,
Mobile: +86 13910100149
cynthia.wang@servier.com

Global BD Coordination
Valérie Coudane
GBD Coordination Officer Oncology
valerie.coudane@servier.com
## Partnering with Servier

**A partner of choice**

**A partner with strong commitment**

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

**A partner with a global presence**

With €4.7Bn of revenue in 2021 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

**A partner with proven expertise and experience**

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

**A partner you can rely on**

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

### Partnering interests

#### Oncology

- **Discovery & Early Clinical Focus**
  - Cancer cell Targeting
    - Synthetic lethality
    - Apoptosis
    - Precision oncology
    - Epigenetic regulators
  - Immunooncology
    - Tumor micro-environment
    - T cell targeting

- **Modalities**
  - Small molecules and biologics (mAbs/bispecifics, ADCs)

- **Late-stage Clinical Focus**
  - Hematologic tumors (NHL, ALL, AML)
  - Solid tumors; GI as a priority

#### Immuno-inflammation

- **Inflammatory & autoimmune disease**
  - Primary Sjögren syndrome
  - Autoimmune diseases
  - And other diseases sharing similar pathophysiological mechanisms

- **Modalities**
  - Small molecules
  - mAb/bispecifics

#### Neuroscience

- **Multiple System Atrophy**
- **Familial Amyotrophic lateral sclerosis**
- **Hereditary forms of Parkinson’s Disease**
- **Spinocerebellar Ataxia**
- **Progressive Supranuclear Palsy**

- **Modalities**
  - Small molecules
  - ASO
  - Targeted Protein Degradation

#### Cardiovascular & Metabolism diseases

Acquire or license market-ready or mature assets for some geographies